Browse the evidence

Nontargeted AOMs can achieve similar benefits in patients with specific genetic obesity disorders compared to common multifactorial obesity.

Practitioners may consider nontargeted AOMs as an alternative for managing obesity in patients with genetic disorders.

GLP-1RA-induced weight loss would lead to a marked decrease in cancer cases over 10 years in adults.

Implementing GLP-1RA treatments could significantly reduce cancer incidence in obese populations.

If GLP-1RAs were made available for all people with obesity and 50% moved into a lower BMI category, there would be a simulated reduction in cumulative cancer cases of 21,443.

Wider access to GLP-1RAs could lead to significant reductions in cancer cases among obese individuals.

Significant reductions in diastolic BP (-1.5 mm Hg) and systolic BP (-1.1 mm Hg) were observed.

Semaglutide may help lower blood pressure in adults.

GLP-1 receptor agonists promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity.

GLP-1 receptor agonists can be considered for managing type 2 diabetes and obesity in clinical practice.

GLP-1 receptor agonists reduce cardiovascular risk and slow progression to renal failure in persons at high risk and those with type 2 diabetes.

Consider GLP-1 receptor agonists for patients at high risk of cardiovascular issues or renal failure.

The preoperative weight loss intervention was feasible and viewed favorably among patients, with 83% feeling that video calls were helpful.

Practitioners can consider using video consultations as a supportive tool for weight loss interventions.

The unique combination of naltrexone and bupropion in NB-ER may work together to target POMC cells to prevent endogenous negative feedback, thereby decreasing appetite.

Understanding the mechanism can help practitioners explain the treatment's effects to patients.

Tirzepatide has potential impacts on diabetes, obesity, NASH, and cardiovascular risks.

Tirzepatide may be beneficial for patients with diabetes and associated comorbidities.

Metabolic adaptation hinders the efficacy of obesity management strategies.

Understanding metabolic adaptation can help practitioners develop more effective obesity management strategies.

Reinitiating semaglutide at the target dose after a treatment gap can lead to adverse effects.

Caution is advised when reinitiating GLP-1 therapy after a gap, especially at target doses.

Therapy lapses with GLP-1 receptor agonists may be prevented by a multi-modal approach.

Implementing a multi-modal strategy can help maintain GLP-1 therapy adherence.

Bariatric surgery is a highly effective intervention to induce weight loss with durability over 10 or more years.

Bariatric surgery can be considered a long-term solution for significant weight loss.

Prevention of overweight and obesity is crucial and should be addressed socially.

Efforts to prevent obesity should involve community and societal strategies.

HEC-CG115 reduced fasting blood glucose and glycated haemoglobin levels similar to those after semaglutide.

HEC-CG115 may provide effective glycaemic control for patients with type 2 diabetes.

Tirzepatide achieved MASH resolution with no worsening of fibrosis in a significantly higher percentage of patients than placebo.

Tirzepatide may be a promising treatment option for patients with MASH, potentially improving liver health.

More patients in the tirzepatide group achieved a 1-stage or greater fibrosis improvement without worsening of MASH compared to placebo.

Tirzepatide may help improve liver fibrosis in patients with MASH.

Tirzepatide has been approved for the treatment of adults with type 2 diabetes who are overweight/obese or have weight-related comorbidities.

Tirzepatide is a viable treatment option for managing type 2 diabetes in specific patient populations.

Lacto-ovo-vegetarians (LOV) and non-vegetarians (NV) showed similar increases in quadriceps femoris muscle thickness (QFMT) after 12 weeks of strength training (ST) (LOV: 9.2 ± 5.4 mm; NV: 5.5 ± 8.1 mm).

Both vegetarians and non-vegetarians can achieve similar muscle growth from strength training.

Both groups experienced similar improvements in knee extension one-repetition maximum (1RM) after 12 weeks of ST (LOV: 24.7 ± 11.1 kg; NV: 21.6 ± 9.8 kg).

Strength training can enhance strength performance similarly in both vegetarians and non-vegetarians.

Lacto-ovo-vegetarians had lower protein consumption than non-vegetarians throughout the study but still achieved adequate protein intake.

Adequate protein intake can be achieved even with lower consumption in vegetarians.

Innovative solutions are needed to implement sustainable lifestyle modification interventions for T2D.

Practitioners should advocate for and develop innovative strategies to enhance lifestyle intervention adherence.

There is a distinct correlation between type 2 diabetes status and the likelihood of heart failure.

Recognizing this correlation can guide healthcare providers in monitoring and managing heart health in diabetic patients.

GLP-1 receptor agonists have demonstrated cardioprotection in patients with type 2 diabetes and heart failure.

Incorporating GLP-1RAs into treatment plans may improve cardiovascular outcomes in diabetic patients.